Goldenseal for Health & Longevity - Quick Reference Sheet

Goldenseal for Health & Longevity

Created on 10/17/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Gemini 4 Argon – Audit

Goldenseal is a woodland root supplement used for blood sugar, cholesterol, and microbial defense. No controlled human study tests whole goldenseal alone; low-level blood sugar, cholesterol, and diarrhea evidence comes indirectly from purified berberine. Conversely, human studies show whole goldenseal blocks drug-processing liver enzymes and alters oral medication absorption. Alongside commercial lead contamination, it has an unfavorable longevity risk-to-benefit profile compared with purified berberine. (Full Review)

Protocol

Botanical vs. purified alkaloid approach
~3,000 mg/day dried root (or 900–1,500 mg/day purified berberine)
Short-term human root extract regimens use 2,280–3,969 mg/day (5–6% alkaloids); purified berberine avoids hydrastine CYP450 blockade
Half-life and split dosing
500–1,000 mg orally 2–3× daily (every 8 hours)
Matches hydrastine 4.8-hour half-life; lower ranges apply for females (1,000–1,500 mg/day), adults >60 years (500–1,000 mg/day for ≤2 weeks), and CYP2D6 poor metabolizers (250–500 mg/day)
Best time of day
With meals or 15–30 minutes before eating
Oral administration with food buffers gastric irritation and aligns with postprandial glucose and lipid absorption; bedtime dosing is avoided to prevent reflux
Time to effect
Atherogenic Lipid & Cholesterol Reduction
4–12 weeks
Indirect LDL-C, total cholesterol, and triglyceride reductions from purified berberine (re-evaluated at 8–12 weeks)
Glycemic Control & Insulin Sensitivity
28 days to 4–12 weeks
28 days for open-label HbA1c shift with goldenseal plus metformin (no FPG change); 4–12 weeks for indirect glycemic changes from purified berberine
Acute Infectious Diarrhea Resolution
8–24 hours
Single 400 mg oral purified berberine sulfate dose reduced 8-hour cholera stool volume and resolved ETEC diarrhea within 24 hours

Benefits

Contraindications
  • Pregnant and breastfeeding women
  • Newborns, infants, and individuals with G6PD deficiency
  • Patients with decompensated diabetes or active hepatobiliary disease (T2DM with HbA1c ≥ 8.0%, DKA, hematologic, hepatic, or renal disease)
  • Patients on narrow-therapeutic-index CYP3A4, CYP2D6, or P-gp drugs (cyclosporine, TKIs such as bosutinib)
Key Interactions
  • Metformin (biguanide antidiabetic) (500–1,500 mg/day)
  • CYP3A4 substrates (midazolam, cyclosporine, tacrolimus, simvastatin, indinavir) (indinavir spared)
  • CYP2D6 substrates (metoprolol, venlafaxine, fluoxetine, tramadol, codeine, tamoxifen)
  • P-gp substrates (digoxin, dabigatran) and OATP/OAT substrates (rosuvastatin, furosemide) (rosuvastatin, furosemide unaltered)
  • Over-the-counter (OTC, non-prescription) drugs (dextromethorphan, diphenhydramine)
  • Supplements with additive alkaloid or metabolic activity (purified berberine, Oregon grape, coptis, kava, black cohosh, cinnamon) (theoretical)
  • Ultraviolet phototherapy and sunlight (psoralen plus UVA [PUVA] therapy, tanning beds) (theoretical)

Risk & Side Effects

  • High: Cytochrome P450 Inhibition & Drug Accumulation
  • Medium: Intestinal Cation Transporter Inhibition & Reduced Metformin Exposure; P-Glycoprotein Modulation & Digoxin Peak Elevation
  • Low: Neonatal Bilirubin Displacement & Kernicterus; Gastrointestinal Distress & Motility Alteration; Hypernatremia & Hyperosmolality in Decompensated Diabetes
  • Speculative: Topoisomerase II-Mediated Hepatocellular Tumorigenicity; Cutaneous & Ocular Ultraviolet-A Phototoxicity

Monitoring

Marker Target Why
ALT 10–40 U/L (standard reference range) Safety check: detects hepatocellular injury from isoquinoline alkaloids or adulterants (discontinuation threshold >3× ULN)
AST 10–40 U/L (standard reference range) Safety check: evaluates hepatobiliary and cellular toxicity alongside ALT (discontinuation threshold >3× ULN)
Total Bilirubin 0.2–1.2 mg/dL (standard reference range) Safety check: monitors for berberine-mediated albumin displacement or hemolysis
FPG 70–99 mg/dL (3.9–5.5 mmol/L) (standard reference range) Expected-change marker & safety check: tracks glycemic reduction or loss of metformin efficacy
HbA1c <5.7% (standard reference range) Expected-change marker: evaluates 8–12 week glycemic trajectory
LDL-C <100 mg/dL (<2.6 mmol/L) (standard reference range) Expected-change marker: assesses LDLR-mediated cholesterol clearance (drawn as part of a complete fasting lipid panel including TC and TG)
Serum Sodium 135–145 mEq/L (standard reference range) Safety check: rules out hypernatremia and hyperosmolality in diabetic or dehydrated states
Concomitant CYP3A4 / CYP2D6 / P-gp Drug Troughs (e.g., Cyclosporine, Digoxin) No established universal target; prescribed agent-specific therapeutic window relative to individual baseline Safety check: detects goldenseal-induced drug accumulation

Cadence: Baseline before initiation; hepatic transaminases (ALT, AST), total bilirubin, and serum sodium rechecked at 2 and 4 weeks; concomitant narrow-therapeutic-index medication troughs drawn immediately before the next dose at baseline, 7–14 days after starting or stopping, and at 2 and 4 weeks; fasting plasma glucose (FPG), HbA1c, and complete fasting lipid panel re-evaluated at 8–12 weeks.

Qualitative Assessment

  • Gastrointestinal tolerance: Daily stool consistency, abdominal comfort, and absence of nausea during mealtime titration.
  • Medication side-effect vigilance: Unusual sedation, dizziness, bradycardia (abnormally slow heart rate), or hypoglycemic symptoms indicating a drug interaction.